Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy.
about
Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseasesAcute liver failure including acetaminophen overdoseMultimodal brain monitoring in fulminant hepatic failureProcoagulant therapeutics in liver disease: a critique and clinical rationale.Protocol based invasive intracranial pressure monitoring in acute liver failure: feasibility, safety and impact on managementAcute liver failure: a management challenge for the practicing gastroenterologistAdvances in critical care hepatology.Structured approach to treat patients with acute liver failure: A hepatic emergencyAcute liver failure in adults: an evidence-based management protocol for cliniciansRecombinant factor VIIa in the treatment of non-hemophiliac bleeding.The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients.Management of bleeding emergencies: when to use recombinant activated factor VII.Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.Evaluation of liver support systems for preclinical testing by animal trials.Brain edema in acute liver failure: can it be prevented? Can it be treated?Heparin-like effect contributes to the coagulopathy in patients with acute liver failure undergoing liver transplantation.Neurological management of fulminant hepatic failure.Prothrombin complex concentrate for critical bleeding.Clinical usefulness of recombinant activated factor VII in patients with liver failure undergoing invasive procedures.Coagulation in hepatobiliary disease.Monitoring of hematological and hemostatic parameters in neurocritical care patients.Small for size liver remnant following resection: prevention and management.Pediatric transplantation: managing bleeding.Small-for-Size Syndrome: Bridging the Gap Between Liver Transplantation and Graft Recovery.Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011.Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.Management of acute liver failure in infants and children: consensus statement of the pediatric gastroenterology chapter, Indian academy of pediatrics.Cost-Effectiveness Analysis of Plasma Versus Recombinant Factor VIIa for Placing Intracranial Pressure Monitors in Pretransplant Patients With Acute Liver Failure.Optimising the care of patients with cirrhosis and gastrointestinal haemorrhage.
P2860
Q24246238-461DDB8C-CC46-4FB8-8B55-1A9F48F034D0Q24647134-CBD3C983-3D42-4962-BECE-3F58112CB413Q26738310-B8B83EF7-AAD0-44C5-BFD6-EF7A585D7A80Q30458618-092F8A27-434F-4092-BF56-A26B81844C86Q33892643-6B7DA9AE-BD2F-430B-88D5-7AEA39D7CBB0Q34105625-1E8C0663-E90F-4C91-AD29-6595CA96A6E3Q35605215-7E680D6E-59A5-4C95-94B7-9A5286E7515EQ35917306-525CA7F4-839E-42E1-AE06-54CAEDE809ACQ36002196-5C8C2DEF-8A9C-4282-B66B-C32CBFE50E05Q36077574-66AB4EF2-EC9C-4EFF-A6C5-2F136D11CD3CQ36150578-BDD7AE4E-1860-4C03-81BF-346D24A3720BQ36349585-F396BB62-5956-4621-BC6A-06F81E7EF931Q36603284-EA52AEC5-2A09-46F6-9031-F8FCF78B42FAQ36616615-3F2A990E-DE4B-4AA6-ADB7-05A40EB1E790Q36742935-AE39DBF4-6815-4A6C-82D6-54C5262CD9E8Q37263145-4B934516-582D-4953-9196-4DF5421F05F5Q37815043-00B92A51-94CF-40E9-8153-E1E00DA73B90Q37897816-7BBE84BF-A17C-49F0-B40C-7A7F79C5E7E5Q37947220-53341F0F-F583-425E-8EC3-B5B3E86F69D9Q37982415-7A37DD56-709D-4759-863C-E5F2D75E3F49Q38248152-BA36D1C6-65BF-4258-8885-070997FAB271Q38267818-DA26CC61-E2F0-4D9C-B05E-5584BA2B0424Q38543318-BE5B022A-6585-495B-B467-B3501DA66710Q40113551-C93BDF7D-1542-4E52-BF1A-A9FFD686744CQ42207090-623485D5-9980-4C4B-8FE6-4B2D698F73EFQ50866803-CEA084EC-413E-4CEA-B244-00677888DB04Q50896616-873742B5-3223-4AE3-BC4A-3B1EDC25E8F3Q51101241-AB25E7A5-B803-4133-82C7-213E1E3A5D1FQ53854125-2C14E04F-7ED4-4F23-95AB-4427844C8DC9
P2860
Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Recombinant activated factor V ...... red with conventional therapy.
@ast
Recombinant activated factor V ...... red with conventional therapy.
@en
type
label
Recombinant activated factor V ...... red with conventional therapy.
@ast
Recombinant activated factor V ...... red with conventional therapy.
@en
prefLabel
Recombinant activated factor V ...... red with conventional therapy.
@ast
Recombinant activated factor V ...... red with conventional therapy.
@en
P2093
P356
P1476
Recombinant activated factor V ...... red with conventional therapy.
@en
P2093
B Gail Macik
Elizabeth E Hespenheide
Kristen O Arseneau
Stephen H Caldwell
Stephen J Bickston
P304
P356
10.1053/JLTS.2003.50017
P577
2003-02-01T00:00:00Z